Iterum Therapeutics plc (ITRM)

$1.4

+0.01 (+0.72%)
Rating:
Recommendation:
-
Symbol ITRM
Price $1.4
Beta 1.412
Volume Avg. 0.37M
Market Cap 17.127M
Shares () -
52 Week Range 0.601-7.05
1y Target Est -
DCF Unlevered ITRM DCF ->
DCF Levered ITRM LDCF ->
ROE -99.32% Strong Sell
ROA -60.83% Strong Sell
Operating Margin -
Debt / Equity 119.84% Buy
P/E 10.77 Strong Buy
P/B 0.53 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ITRM news


Mr. Corey Fishman
Healthcare
Biotechnology
NASDAQ Capital Market

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.